Nombre: Ramìrez Corona Vrissa Vanessa. B-learning 56

Myriad Genetics Ending Patent Dispute on Breast Cancer Risk Testing

By ANDREW POLLACK JAN. 27, 2015

Myriad Genetics has essentially given up trying to stop other companies from offering tests for increased risk of breast cancer, ending a dispute that was the subject of a landmark Supreme Court ruling that human genes cannot be patented.

The company has settled or is in the process of settling patent-infringement lawsuits it filed against other companies that now offer such testing, a Myriad spokesman said on Tuesday.

Myriad’s lucrative monopoly on testing for mutations in two genes linked to an increased risk of breast and ovarian cancer ended in 2013, when the Supreme Court ruled that human genes were not eligible for patents because they were products of nature.

Numerous laboratories began offering tests, some for much less than the roughly $4,000 Myriad charged for a complete analysis of the two genes, known as BRCA1 and BRCA2.

Myriad sued many of those companies, saying they were infringing other patent claims that had not been invalidated by the Supreme Court.

But last March, a federal district judge in Utah ruled against Myriad’s request for a preliminary injunction against one competitor, Ambry Genetics. Last month, the Court of Appeals for the Federal Circuit upheld the lower court’s decision and ruled that those remaining claims were also ineligible for patents.

After that ruling, “we decided it was in the best interest of the company to settle these matters,” the Myriad spokesman, Ronald Rogers, said.

Settlements have been reached with LabCorp, Invitae and Pathway Genomics. Mr. Rogers said Myriad was in talks with Ambry, Quest Diagnostics, GeneDx and Counsyl.

In the settlements announced so far, the companies have agreed to dismiss the claims and counterclaims against one another, and Myriad has promised not to sue the companies on any remaining patents in the litigation.

Myriad is shifting from the BRCA gene test to a more comprehensive test of 25 genes linked to cancer risk. It is also developing new types of tests to reduce its reliance on the BRCA test.

Nombre: Ramìrez Corona Vrissa Vanessa. B-learning 56

1. Completa la siguiente tabla con palabras del texto aportando ejemplos para todas las categorías gramaticales que recuerdes.

Línea Palabra(s) categoría gramatical significado

1 given verbo dado1 essentially adverbio esencialmente1 has verbo ha3 was verbo haya3 human adjetivo humanos4 cannot verbo no pueden5 company sustantivo compañía6 filed verbo interpuso6 against preposición contra6 now adverbio ahora6 offer verbo ofrecen7 said verbo dijo7 Tuesday adverbio martes8 linked adjetivo relacionados

12 laboratories sustantivo laboratorios9 ended verbo terminó

10 ruled verbo determinó19 Last month adverbio El mes pasado

2. Identifica las siguientes categorías gramaticales marcando en el texto con el color correspondiente.

10 Sustantivos10 adjetivos10 verbos5 adverbios5 preposiciones

3. Traduce las siguientes frases nominales.

ending a dispute poniendo fin a una controversia

other companies that now offer such Otras empresas que ahora ofrecen

Nombre: Ramìrez Corona Vrissa Vanessa. B-learning 56

testing estas pruebas

on testing for mutations en las pruebas para las mutaciones

that human genes were not eligible for patents

que los genes humanos no eran objetos de patentes

Numerous laboratories began offering tests

Numerosos laboratorios comenzaron a ofrecer pruebas

a complete analysis of the two genes, known as BRCA1 and BRCA2

un análisis completo de los dos genes, conocidos como BRCA1 y BRCA2

last March en marzo pasado

a federal district judge in Utah un juez federal de distrito en Utah

Last month El mes pasado

the settlements announced so far los asentamientos anunciados hasta el momento

the companies have agreed las compañías han acordado

a more comprehensive una pruebas más completa

4. Copia del texto enunciados identificando las siguientes estructuras debajo de cada título.

SUJETO

Myriad Genetics has essentially given up trying to stop other companies from offering tests for increased risk of breast cáncer.

The company has settled or is in the process of settling patent-infringement lawsuits.

the Supreme Court ruled that human genes were not eligible for patents because they were products of nature.

Myriad sued many of those companies. a federal district judge in Utah ruled against Myriad’s request for a

preliminary injunction against one competitor, Ambry Genetics. the Court of Appeals for the Federal Circuit upheld the lower court’s

decisión.

Nombre: Ramìrez Corona Vrissa Vanessa. B-learning 56

the companies have agreed to dismiss the claims and counterclaims against one another.

Myriad is shifting from the BRCA gene test to a more comprehensive test of 25 genes linked to cancer risk.

COMPLEMENTO DIRECTO

Myriad Genetics has essentially given up trying to stop other companies from offering tests for increased risk of breast cáncer.

the Supreme Court ruled that human genes were not eligible for patents because they were products of nature.

Myriad sued many of those companies. a federal district judge in Utah ruled against Myriad’s request for a

preliminary injunction against one competitor, Ambry Genetics. the Court of Appeals for the Federal Circuit upheld the lower court’s

decisión.

COMPLEMENTO INDIRECTO   (quien,  para quien)

Myriad Genetics has essentially given up trying to stop other companies from offering tests for increased risk of breast cáncer.

Myriad has promised not to sue the companies on any remaining patents in the litigation.

It is also developing new types of tests to reduce its reliance on the BRCA test.

COMPLEMENTO CIRCUNSTANCIAL (marca L, T, M, para identificar si es de lugar, tiempo o modo).

o Tiempo. The company has settled or is in the process of settling

patent-infringement lawsuits it filed against other companies that now offer such testing, a Myriad spokesman said on Tuesday.

o Tiempo. Myriad’s lucrative monopoly on testing for mutations in two

genes linked to an increased risk of breast and ovarian cancer ended in 2013, when the Supreme Court ruled that human genes were not eligible for patents because they were products of nature.

o Tiempo/Lugar. But last March, a federal district judge in Utah ruled

against Myriad’s request for a preliminary injunction against one competitor, Ambry Genetics.

Nombre: Ramìrez Corona Vrissa Vanessa. B-learning 56

o Tiempo. Last month, the Court of Appeals for the Federal Circuit

upheld the lower court’s decision and ruled that those remaining claims were also ineligible for patents.

o Tiempo. After that ruling, “we decided it was in the best interest of

the company to settle these matters,” the Myriad spokesman, Ronald Rogers, said.

o Tiempo. In the settlements announced so far, the companies have

agreed to dismiss the claims and counterclaims against one another.

5. Mapa Mental. Elabora un mapa mental del texto.